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Human pluripotent stem cells (PSCs) offer a scalable alternative to primary
and transformed human tissue. PSCs include human embryonic stem cells,
derived from the inner cell mass of blastocysts unsuitable for human implan-
tation; and induced PSCs, generated by the reprogramming of somatic cells.
Both cell types display the ability to self-renew and retain pluripotency,
promising an unlimited supply of human somatic cells for biomedical appli-
cation. A distinct advantage of using PSCs is the ability to select for genetic
background, promising personalized modelling of human biology ‘in a dish’
or immune-matched cell-based therapies for the clinic. This special issue will
guide the reader through stem cell self-renewal, pluripotency and differen-
tiation. The first articles focus on improving cell fidelity, understanding
the innate immune system and the importance of materials chemistry, bio-
fabrication and bioengineering. These are followed by articles that focus
on industrial application, commercialization and label-free assessment of
tissue formation. The special issue concludes with an article discussing
human liver cell-based therapies past, present and future.
This article is part of the theme issue ‘Designer human tissue: coming to
a lab near you’.
The human body is composed of hundreds of different cell types that derive
from pluripotent stem cells (PSCs). During development in utero and after
birth, different stem cell populations perform vital functions in the body. These
range from coordinated tissue morphogenesis during gestation, to tissue renewal
and homeostasis in the adult. Essential to these processes is hierarchical control of
cell potency. In the developing embryo and the adult, cell fate is determined by
niche-specific factors and executed through defined changes in gene expression.
A good example of cell fate determination is observed in PSCs, with the stem
cell master regulators, Oct-4, Sox 2 and Nanog serving to instruct stem cell
self-renewal and differentiation (for a review, see [1]).
Development starts with the fertilized egg cell, and totipotent blastomere
formation, capable of forming embryonic and extra-embryonic tissues. At the
point of blastocyst formation, the pluripotent cells of the inner cell mass
are capable forming all three germ layers in the developing embryo, with
the trophectoderm contributing to extra-embryonic tissues [2]. As develop-
ment proceeds germ layer segregation takes place and multipotent stem cell
populations are formed and differentiate into specialized tissues of the
fetus. Following birth, multi, bi and unipotent stem cell populations persist
in the neonate and the adult, serving to instruct development and/or tissue
maintenance.
Since the 1980s, PSCs have taken centre stage as a promising cell candidate
to model and treat human diseases. The successful isolation and culture of
murine PSCs was presented in 1981 and heralded a new era in cell biology,
driving important advances in our understanding of mammalian physiology
[3,4]. It was a further 17 years before the first human embryonic stem cell
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lines were isolated [5]. These studies were pivotal to
endeavours in modelling human physiology and developing
cell-based therapies. The use of PSC-based systems will likely
lead to new regulated cell-based assays in the near term, with
tissue repair in vivo a longer-term aspiration. To date, a
number of hESC-derived products are in clinical trials, includ-
ing macular degeneration, diabetes and heart disease, with
some other applications registered for clinical trial approval
[6–8]. iPSCs have been used in the clinic, with one experimen-
tal procedure performed on an individual with macular
degeneration [9]. Next year, clinical trials will commence
using PSC-derived dopaminergic neurons to treat Parkinson’s
disease. The output from those well-controlled clinical trials
will determine the suitability of PSCs for developing pioneer-
ing cell-based therapies. Although both types of PSCs are
renewable, a distinct advantage of using iPSC-based systems
is the ability to select for genetic background, promising per-
sonalized modelling of human biology ‘in a dish’ and/or
immune-matched cell-based therapies for the clinic.
The landmark discovery that mammalian DNA, from a
fully differentiated cell, could be reprogrammed to pluripo-
tency leading to the birth of viable offspring [10] inspired
the successful induction of pluripotency in mammalian
somatic cells [11]. Reprogramming success was quickly
extended to human somatic cells, providing a major advance
for the field [12]. The successful isolation of PSCs and induc-
tion of pluripotency were deemed so important for basic
research that two Nobel prizes in Physiology or Medicine
were awarded in 2007 and 2012, respectively. The ability of
PSCs to self-renew and form all cell types in the embryo
proper is a distinct advantage and offers a scalable alternative
to primary and transformed human tissue. Initially, stem cell
reprogramming relied on retrovirus transduction to deliver
transgene activity to the cells [11,12]. While this was impor-
tant for proof of concept, retroviral and lentiviral transgene
integration is problematic for basic or clinical research trans-
lation, therefore insertion-free strategies were developed (for
a review, see [13]).
Since those seminal studies, there has been a global push
to exploit PSC-based technology to challenge our under-
standing of human biology and to treat disease. Key
outputs from these studies have been the generation of
high-fidelity human models ‘in a dish’ and pioneering cell-
based therapies to treat human disease. Stem cell-derived
models have been developed for many tissues, including
gut, liver and brain to name a few [14–16]. Stem cell-derived
tissue systems have also been employed to study human dis-
ease [16], to study adverse drug reactions [17] and human
susceptibility to viral infection [18]. Most recently, the devel-
opment of efficient three-dimensional culture and organoid
methodologies, combined with microfluidic platforms, have
provided significant advances for the field, promising
higher-fidelity datasets and perfused human tissue [19].
Annually, more than 115 million animals are used world-
wide in experimentation [20]. While those experimental
models provide valuable information, they do not efficiently
extrapolate to human physiology, with an estimated 10% suc-
cess rate [21]. This provides a strong rationale to develop
more predictive human models. Consequently, there have
been numerous studies focused on the delivery of defined
and scalable human tissue systems. Key to producing high-
fidelity tissue in vitro is the recreation of the nascent tissue
structure, with the appropriate niche factors [22]. Attempts
to achieve this in vitro and in vivo have seen scientists from
chemistry, biology, physics and engineering backgrounds
working together. This has led to exciting developments in
human tissue engineering. With this in mind, we have pre-
pared this special edition of the journal and invited
contributions from experts around the world to describe
cutting-edge activity in their fields and future directions.
We begin with a review of the progress made in the
field of PSC reprogramming and self-renewal written by
Abu-Dawud et al. [23]. This is followed by articles that
examine the PSC somatic cell differentiation. The first
article, written by McComish & Caldwell [24], focuses on
brain differentiation. This is followed by an article review-
ing gastrointestinal differentiation, written by Fair et al.
[25]. The next article, written by Tam et al. [26], reviews
musculoskeletal differentiation. We continue the somatic
cell differentiation theme with articles focusing on the
immune system. Macrophage differentiation from iPSCs is
presented by Lopez-Yrigoyen and co-workers [27]. This is
followed by an article on the innate immune system written
by Fischer and co-workers [28]. Following on from somatic
cell differentiation, Lyall and co-workers [29] present the
use of a semi-automated differentiation system to model
fatty liver disease.
Essential to the generation of cell-based models and
therapies is the quality of the in vitro engineered tissue.
Underpinning success in technology scale-up and application
is the development of the raw materials required to produce
the somatic cells at clinical grade. A key consideration is the
extra-cellular matrix used in the production process and
this is reviewed by Hagbard and co-workers [30]. Recently,
the use of technologies that examine global patterns of gene
expression facilitated major improvements in cell and pheno-
type and scale-up [31,32]. Such advances are also necessary
to assure the quality of PSC-based products. The use of bio-
informatics to control stem cell differentiation is reviewed
by Godoy and co-workers [33]. This is followed by an article
by Meisig & Blu¨thgen [34] dealing with the deconstruction of
cell signalling equilibria to build bona fide tissue from PSCs.
In recent years, tremendous progress has been made in
the development of organoids from human tissue [35,36].
These studies are exciting, but for organoids to offer signifi-
cant promise they must be manufactured at scale, using
defined additives. Developments in this field of research are
reviewed by Alhaque and co-workers [37]. In order to deliver
engineered tissue at scale, it will be necessary to further opti-
mize the cell niche and automate the production process.
Materials chemistry provides a unique opportunity to ident-
ify new materials that can be used to structure, scale and
stimulate appropriate tissue formation in vitro [38]. Recent
progress in the field is reviewed by Schmidt and co-workers
[39]. Following on from this, Skeldon and co-workers [40] dis-
cuss the importance of cell bioprinting in the quest to
generate human tissue. This is followed by Brown & Khetani
reviewing the microfabrication of stem cell-derived tissue for
cell-based screening [41]. Stem cell-derived somatic cells have
already shown significant promise within industry [17]. For
these models to progress further, there are further technologi-
cal considerations. This is dealt with in an opinion piece
article, written by Williams from Astra Zeneca [42].
The ability to produce high-fidelity human tissue from
stem cells for basic and clinical application requires the devel-
opment of non-invasive monitoring technology that can
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measure and report in real time. The merits of label-free
monitoring are reviewed by Gamal and co-workers [43].
We end this special issue with an article by Iansante and
co-workers [44], which reviews the progress made in devel-
oping human cell-based therapies to treat compromised
liver function and promote organ regeneration.
We are extremely grateful to the authors, the reviewers
and the editorial team at Philosophical Transactions B for
their time and effort in delivering this special edition of the
journal. We hope that this collection of papers stimulates
interest and collaboration within the field, with a focus on
translating basic scientific concepts into game-changing
regenerative medicines for the clinic.
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